Regeneron’s Pasatru Wins FDA Approval in Ultra-Rare ‘Stone Man Disease’
▫️Regeneron Has Won US FDA Approval For Pasatru (Garetosmab-grts) in A Rare Connective Tissue Disorder, Placing It in Direct Competition With Ipsen’s Sohonos (Palovarotene).
▫️Pasatru Is Approved to Reduce New Heterotopic Ossification And Reduce Clinician-Assessed Disease Flare-Ups in Adults With Fibrodysplasia Ossificans Progressiva (FOP).
▫️The Monoclonal Antibody (mAb), Which Is Administered Intravenously Once Monthly, Works by Blocking Activin A - A Protein Critical in The Development of Lesions in FOP Patients.
▫️FOP Is An Ultra-Rare Genetic Disorder in Which Muscles, Tendons, Ligaments And Other Connective Tissues Are Progressively Infiltrated by Rogue Bone Formation, A Process Known As Heterotopic Ossification.
▫️When This Happens in The Jaw, Spine, or Rib Cage, Basic Daily Activities Can Become Limited. In Theory, This Creates A Second Skeleton, Which Is Why The Condition Is Also Known As “Stone Man Disease.
@MedicalNoteBook
